Revolutionizing Cancer Treatment
Empiriko is a biotech company focused on developing targeted radioligand therapies and antibody drug conjugates for cancer and next generation point-of-care diagnostics.
Key Features of Drug Delivery Platform
Personalized precision medicine is redefining the next generation of health care. Empiriko has developed a suite of integrated technologies that leverage advances in medicinal chemistry, immunology, engineering and computational modeling to connect its portfolio of radioligand therapies and antibody drug conjugates with its next generation disease/drug monitoring device for use in the home or clinic. The synergistic applications and benefits of these integrated technologies create a disruptive model with the potential to revolutionize personalized care and cost-effectively improve patient outcomes.
Targeted Drug Delivery System
R*ECL-AI-M™: Empiriko’s Radioligand Enhanced Cancer Treatment via Linker-Antibody Immunotherapy Macrocycles Technology provides a scalable platform to deliver targeted radioligand therapy, radio-chemo biologic dual therapy, and antibody drug conjugates to cellular targets anywhere in the body. This promising advancement in radioligand therapy (RLT) which links radioactive and chemical payloads to specific antibodies, can be used as a “theranostic” agent to focus radiation-based imaging (diagnostic) and therapeutic interventions with limited side effects to adjacent/healthy tissues.
Remote Monitoring for Disease and Drug Analysis
PMF™: Personalized Metabolic Fingerprint™ Device is next generation personalized diagnostics to monitor disease and drug response for at-risk patients at home in real-time. The device includes 3D printed miniaturized mass spec for drug analysis and immunochemical biochip for disease detection. The PMF™ device is physician prescribed, fully automated, and affordable. Empiriko’s initial focus is to monitor patients pre/during/post cancer treatment and at-risk patients with cardiovascular disease for better clinical outcomes.
The synergies created by connecting the data flow between these platforms enable the company to cost-effectively accelerate drug development, expand patient access and customize patient treatment for improved clinical outcomes.
Leadership
Pam Randhawa, MPM, CEO & Founder
Pam Randhawa, CEO and Founder of Empiriko, has over 25 years of leadership experience in the healthcare/life sciences industries with expertise ranging from policy, corporate strategy, product development, advanced analytics and marketing for Fortune 500 companies, startups, and government.
Daniel Steinberg M.D., CMO
Daniel Steinberg M.D., Empiriko’s Chief Medical Officer, has been a practicing physician for over 30 years, specializing in allergy/clinical immunology. Prior to pursuing his medical training, Dr. Steinberg worked in the biotechnology industry where he developed interdisciplinary solutions to medical, business and scientific challenges in a variety of clinical and industrial settings.
Scientific Advisory Board
Dennis Ausiello, M.D.
Physician-in-Chief, Emeritus, MGH
Dennis Ausiello, M.D. is the Director of the Center for Assessment Technology and Continuous Health (CATCH), Physician-in-Chief, Emeritus at Massachusetts General Hospital and Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School.
Gopal Bhatnagar, M.D.
Chief, Heart, Vascular & Thoracic Institute
Cleveland Clinic, Abu Dhabi
Dr. Gopal Bhatnager, M.D., is Institute Chief of the Heart, Vascular & Thoracic Institute at Cleveland Clinic Abu Dhabi. Prior to joining Cleveland Clinic Abu Dhabi, Dr. Bhatnagar served as Chief of Staff at Trillium Health Centre, Ontario, Canada.
Eric N. Jacobsen, Ph.D., Professor,
Dept. of Chemistry, Harvard University
Eric N. Jacobsen, Ph.D. is the Sheldon Emery Professor of Chemistry at Harvard University where he has been a faculty member since 1993 and previously served as Chair of the Department of Chemistry and Biology.
Sir Richard Roberts, Ph.D., Nobel Laureate
CSO, New England Biolabs
Sir Richard Roberts, Ph.D., an entrepreneur, molecular biologist, and architect of gene-splicing, is the Chief Scientific Officer of New England Biolabs, where he has been a Director of Research since 1992. Before moving to NEB, he was at Cold Spring Harbor Laboratories, where he reached the position of Assistant Director for Research under Dr. James. D. Watson.
Rakesh Suri, M.D., D.Phil.
Head, Robotic Cardiac Surgery,
Corewell Health
Rakesh M. Suri, MD, DPhil. is a globally recognized thought leader and pioneering cardiac surgeon with expertise in heart valve disease, robotics, transcatheter technology and complex multivalve pathology. He is a leader who has spearheaded the development of innovative models of healthcare delivery, international enterprise growth and organizational transformation in pursuit of value at Mayo Clinic and Cleveland Clinic.
Mukund Chorghade, Ph.D., VP, Chemistry
Mukund Chorghade Ph.D. is VP of Chemistry at Empiriko, has over 35 years of experience in drug discovery, chemical route selection, process development and formulations design for academic and industry-sponsored research on New Chemical Entities and generics.